Abstract
Heart rate lowering has an important role in the treatment of coronary artery disease. Lower heart rates extend diastolic filling, facilitating improved myocardial perfusion and reduced myocardial oxygen demand. This has traditionally been achieved with beta-blockers or calcium-channel blockers. Unfortunately both these classes of drugs have sideeffects in a significant minority of patients. The recent development of ivabradine, which acts specifically on the sinoatrial node, offers promise in achieving heart rate reduction without major side effects. Ivabradine selectively and specifically inhibits the If channel which is integral to the generation of the pacemaker current in the sinoatrial node. Initial studies utilising ivabradine show improvements in exercise tolerance and time to developing ischaemia during exercise in patients with chronic stable angina. Ivabradine has no negative inotropic effects and does not appear to have any major side-effects. It has been shown to have similar antianginal and anti-ischaemic effects to atenolol and amlodipine. Animal studies have suggested that ivabradine may have beneficial effects in chronic heart failure leading to improvements in left ventricular function. In humans with stable coronary artery disease, left ventricular dysfunction and heart rates of 70bpm or more, ivabradine appears to reduce rates of revascularisation and hospitalisation for myocardial infarction.
Keywords: Funny channel, Ivabradine, chronic stable angina, heart rate lowering
Current Drug Therapy
Title: Sinus Node If Channel Inhibition – A New Therapeutic Approach to Heart Rate Lowering
Volume: 4 Issue: 1
Author(s): Anne E. Scott, Kirsten Kruszewski and Stephen J. Leslie
Affiliation:
Keywords: Funny channel, Ivabradine, chronic stable angina, heart rate lowering
Abstract: Heart rate lowering has an important role in the treatment of coronary artery disease. Lower heart rates extend diastolic filling, facilitating improved myocardial perfusion and reduced myocardial oxygen demand. This has traditionally been achieved with beta-blockers or calcium-channel blockers. Unfortunately both these classes of drugs have sideeffects in a significant minority of patients. The recent development of ivabradine, which acts specifically on the sinoatrial node, offers promise in achieving heart rate reduction without major side effects. Ivabradine selectively and specifically inhibits the If channel which is integral to the generation of the pacemaker current in the sinoatrial node. Initial studies utilising ivabradine show improvements in exercise tolerance and time to developing ischaemia during exercise in patients with chronic stable angina. Ivabradine has no negative inotropic effects and does not appear to have any major side-effects. It has been shown to have similar antianginal and anti-ischaemic effects to atenolol and amlodipine. Animal studies have suggested that ivabradine may have beneficial effects in chronic heart failure leading to improvements in left ventricular function. In humans with stable coronary artery disease, left ventricular dysfunction and heart rates of 70bpm or more, ivabradine appears to reduce rates of revascularisation and hospitalisation for myocardial infarction.
Export Options
About this article
Cite this article as:
Scott E. Anne, Kruszewski Kirsten and Leslie J. Stephen, Sinus Node If Channel Inhibition – A New Therapeutic Approach to Heart Rate Lowering, Current Drug Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488509787081859
DOI https://dx.doi.org/10.2174/157488509787081859 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Early Functional and Structural Microvascular Changes in Hypertension Related to Aging
Current Hypertension Reviews Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
Current Cardiology Reviews The Woman’s Heart: Insights into New Potential Targeted Therapy
Current Medicinal Chemistry Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Current Hypertension Reviews CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design Chemical Connexin Impairment in the Developing Gonad Associated with Offspring Infertility
Current Medicinal Chemistry Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists
Current Pharmaceutical Design Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine Role of Oxidative Stress and Mitochondrial Dysfunction in Skeletal Muscle in Type 2 Diabetic Patients
Current Pharmaceutical Design Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Myocardial Infarction Following Atherosclerosis in Murine Models
Current Drug Targets Cytoprotection by Natural and Synthetic Polyphenols in the Heart: Novel Mechanisms and Perspectives
Current Pharmaceutical Design Therapeutic Apheresis in Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Updated Role of Nitric Oxide in Disorders of Erythrocyte Function
Cardiovascular & Hematological Disorders-Drug Targets The Activated Endocannabinoid System in Atherosclerosis: Driving Force or Protective Mechanism?
Current Drug Targets Antidiabetics: Structural Diversity of Molecules with a Common Aim
Current Medicinal Chemistry Adult Stem Cell Transplants for Spinal Cord Injury Repair: Current State in Preclinical Research
Current Stem Cell Research & Therapy Novel approaches to examine the regulation of voltage-gated calcium channels in the heart
Current Molecular Pharmacology